Ariceum Therapeutics
Dennis Mewis has a diverse work experience in the field of radiopharmaceutical research and development. Dennis is currently serving as the Head of Laboratory - CMC & Radiopharmaceutical R&D at Ariceum Therapeutics since January 2022. Prior to this, they worked at OctreoPharm Sciences GmbH where they supported the outsourcing of the radiopharmaceuticals segment and was involved in radiopharmaceutical R&D from August 2011 to December 2021. Dennis also worked as a chem.-tech. Assistent at Eckert & Ziegler Radiopharma GmbH from December 2011 to December 2013. Dennis gained experience as a chem.-tech. Assistent at Charité from June 2010 to June 2011 and as a Chemielaborant from August 2009 to June 2010. Dennis also worked as a Chemielaborant at Freie Universität Berlin from June 2009 to July 2009.
Dennis Mewis has a diverse education history in the field of technology and chemistry. Dennis started their education in 2006 at Freie Universität Berlin, where they studied to become a Chemielaborant. During this time, they focused on subjects such as Chromatografie, Spektroskopie, and Reaktionsführung. In 2009, Dennis moved on to Kläre-Bloch-Schule Berlin, where they obtained their Fachabitur degree in Technik. Additionally, in the same year, they attended Lise-Meitner-Schule in Berlin to become a chem.-tech. Assistent. Finally, they completed their formal education as a Chemielaborant in 2009 at Lise-Meitner-Schule, Berufsschule in Berlin.
This person is not in any teams
Ariceum Therapeutics
1 followers
Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers.177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, isan antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.